LTZ Therapeutics
PrivateLast Round
Series B
May 6, 2026
Total Funding Raised
$115M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
LTZ Therapeutics operates in Healthcare & Life Sciences and is based in Redwood City, California. Its latest recorded funding round was a Series B round in May 2026.
LTZ Therapeutics is a biotechnology company that develops innovative immunotherapies for cancer and autoimmune diseases using its proprietary Myeloid Engager Platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
LTZ Therapeutics Comparables
Compare LTZ Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CREATE Medicines | 81% | |
| Elpiscience Biopharmaceuticals | 79% | |
| Bolt Biotherapeutics | 78% |
For institutional investors. Book with your work email.
LTZ Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 6, 2026 | ||||
| Series A Extension | Apr 24, 2025 | ||||
| Series A | Jul 30, 2024 | ||||
| VC Round | May 31, 2023 | ||||
| Seed | Apr 7, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
LTZ Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lanchi Ventures | Series B, Series A Extension |
| Boyu Capital | Series B, Series A Extension |
| Zoo Capital | Series A Extension |
| Hillhouse Investment | Series A, Series A Extension, Series B |
| Lapam Capital | Series A Extension, Series A |
| China Investment Corporation | Series B |
| Unicorn Capital Partners | Series A Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 50% MoM.
- Jun 20, 2026
Monthly visitors increased 138% MoM, reaching 2.7K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_awardNov 5, 2026
LTZ Therapeutics Inc. is selected as the winner of the “Immunology Innovation of the Year” award in the annual BioTech Breakthrough Awards program in California on Nov 5th '26.
- recognized_asNov 5, 2026
On Nov 5th '26, BioTech Breakthrough recognizes LTZ Therapeutics Inc. as the 2026 Immunology Innovation of the Year winner in its annual BioTech Breakthrough Awards program in California.
- is_developingOct 29, 2026
LTZ Therapeutics Inc. is developing its U-MCE(TM) Platform to enhance the phagocytic function of monocytes and macrophages and foster anti-tumor immunity.
- is_developingAug 17, 2026
In Aug '26, California-based LTZ Therapeutics Inc. is developing its own Universal Myeloid Cell Engager (U-MCE(TM)) Platform to enhance the phagocytic function of monocytes and macrophages, foster anti-tumor immunity, and potentially treat non-oncology diseases.
- hiresAug 17, 2026
LTZ Therapeutics Inc. appoints Phillip Lee as Chief Financial Officer, effective immediately, in California on Aug 17th '26.
For institutional investors. Book with your work email.
LTZ Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about LTZ Therapeutics's valuation, stock price, and market status.
Is LTZ Therapeutics a public or private company?
LTZ Therapeutics is a private company.
What is the current stock price of LTZ Therapeutics?
LTZ Therapeutics is a private company, so its shares have no public market price. Caplight tracks LTZ Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is LTZ Therapeutics worth (valuation)?
Valuation information for LTZ Therapeutics is not publicly available.
Can I buy LTZ Therapeutics stock?
LTZ Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was LTZ Therapeutics's last funding round?
LTZ Therapeutics's most recent funding round was Series B on May 6, 2026.
Who are the main investors in LTZ Therapeutics?
Key investors in LTZ Therapeutics include Boyu Capital, Hillhouse Investment, Lapam Capital, 险峰K2VC, Qiming Venture Partners.
Will LTZ Therapeutics IPO soon?
No public IPO plans have been announced for LTZ Therapeutics.
How can I track LTZ Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in LTZ Therapeutics's shares on secondary markets.